Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2005

View Archived Issues

Inhibition of MMPs may emerge as an antidiabetic strategy

AVI BioPharma commences phase II clinical trials of Resten-MP

New safety information for Celebrex in Canada

Lyrica now available in U.S.

Exelixis begins new phase I trials for three compounds

ReNeuron holds pre-IND meeting for ReN-001 stem cell therapy

Dimethaid Research shareholders approve name change to Nuvo Research

12-week results of ISA-247 phase III study in psoriasis

Phase II study evaluates CA4P triple combination therapy for ovarian cancer

SHEPHERD study of eculizumab for PNH completes enrollment

Ceregene begins phase I study of novel gene therapy for Parkinson's disease

AEG-35156 enters second phase I study

Laureate Pharma to supply Enobia with sPHEX metallopeptidase for phase I trials

First phase I results for insomnia drug NG2-73

Altastaph recommended to receive orphan medicinal product status in Europe

Arimoclomol begins phase II trial, receives fast track status

New therapeutics for cancer disclosed in recent patents

Novel agents for arthritis and related disorders reported

New anti-HIV agents described in recent patents

HCV RNA polymerase inhibitors claimed in Japan Tobacco patent

New data presented on AC-100

TGF-beta signaling pathways implicated in liraglutide's efficacy for type 2 diabetes

FK-614 improves insulin sensitivity both in the liver and in peripheral tissues

MicroRNA --a compelling target for anti-HCV therapy

BVT-2733 improves energy balance and glucose homeostasis in diet-induced obesity

DPP-IV inhibition does not affect physiological tissue microcirculation

Sildenafil and testosterone work synergistically in hypogonadal men

Good PK profile reported for AMG-162 in postmenopausal women

Topical BAL-10092 reduces skin inflammation in preclinical and human models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...